Rod Raynovich
Contributor since: 2010
Company: Raygent Capital
Latest Articles
Biotech ETFs In A Bull Market: Positioning For A Q4 Rally
2015 Biotech Stock Preview: Rhythms Of The 'PermaBull'
Biotech Stocks Get Turbo Boost From Idenix Deal
Biotech Rout Not Surprising: Surveying The Damage
Large-Cap Biopharmaceuticals Are Core Holdings After Sell-Off: AbbVie, Amgen, Gilead
Biotech Bull Market Up 6%+ YTD: Key Trends To Watch Update #2
Biotech Bull Market Key Trend No. 1: 5 Large Cap Biopharmas Plus 2
Biotech Bull Market: 2014 Key Trends To Watch
NanoString Technologies: An Emerging Growth Play In Molecular Diagnostics
'Long Only' Funds? Shorting Stocks Is So 2008
Valuation Models For Biopharmaceutical Stocks
Are Biotech M&A Premiums Already Built In? Valuations Do Matter
Emerging Biomarker Companies Redux: Positioned For Growth
Biotech Stocks Get A Turbo Boost From Vertex
Is There No End To The Biotech Bull Market?
Biopharmaceutical Sector Attempts Another Move To New Highs
Biotech Bull Market: Are ETFs Better Than Mutual Funds?
Update On Emerging Biomarker Diagnostics: BG Medicine, Response Genetics, Vermillion
Who Knows About The Bull Market In Biotech Stocks?
Biotech Sector Avoids Nasty Correction And Hits New Highs
Consolidation Continues In Mid Cap DX Companies: Bull Market In Biotech Hits New Highs
Emerging Biomarker Diagnostics: BGMedicine And Vermillion
Biotech Bull Market Intact: Rayno Biopharmaceutical Portfolio Outperforms
Response Genetics Stock Soars 31% On $7.8M Offering News
Technology Convergence Trends in the Biopharma Sector: Abbott, Alere and Merge
Life Science Portfolios: Reflecting on a Year of Out-Performance
Explore the Many Flavors of Healthcare Stocks: Biotech, Drugs, Life Sciences, MedTech
Balance Your Portfolio With Three Stable Biotech ETFs
Novel Diagnostic Tests Utilizing Biomarkers Working Well for Vermillion
Cardiovascular Systems Gains Traction
Immucor Cuts Guidance on Lower Demand
Successful IPOs in Genomics Could Ignite Biotech Stocks